TipRanks
Go Ultimate55% OFF

ATS Corporation (ATS) AI Stock Analysis

64 Followers
ATS

ATS Corporation

(NYSE:ATS)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Bookings and BacklogHigh bookings and a sizable, diversified backlog provide multi-quarter revenue visibility and show demand for ATS automation across life sciences. The breadth of applications and enterprise orders can support repeat programs and reduce reliance on any single customer or end market as orders convert.
Negative Factors
Profitability CompressionTTM net income was only $8.6M with a 0.3% net margin, while EBIT margin fell to 5.8% from 6.7% in FY2026. This sharp earnings compression weakens self-funded growth, reduces returns on capital, and leaves less cushion if execution or demand remains pressured.

ATS Corporation (ATS) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%ATS-38.22%SPY+9.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.39B
Dividend Yield
―
Average Volume (3M)
264.96K
Price to Earnings (P/E)
253.0
Beta (1Y)
1.02
Revenue Growth
7.23%
EPS Growth
―
Country
US
Employees
7,000
Sector
Industrials
Sector Strength
63
Industry
Industrial - Machinery

ATS Corporation Business Overview & Revenue Model

Company Description

ATS Corporation, operating globally through its subsidiaries, delivers comprehensive automation solutions. The company's expertise spans the entire lifecycle of automated manufacturing and assembly systems, encompassing planning, design, construction...

ATS Corporation Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q2-2027)|% Change Since:-10.50%|Next Earnings Date:Feb 09, 2027
Earnings Call SentimentNeutral

The call presented strong bookings, a record and diversified life sciences backlog, attractive nuclear and radiopharma opportunities, improved cash flow, and progress on the fixed cost transformation program. However, these positives were offset in the near term by revenue and earnings declines, margin compression, tariff-related order delays, withdrawn fiscal-year growth and margin objectives, longer backlog conversion timelines, restructuring actions, and leverage above the target range. Overall, the outlook was balanced, with management confident in medium- and long-term growth but acknowledging meaningful near-term execution and demand challenges.

Positive Updates

Strong Order Bookings and Backlog
Q2 order bookings were $827 million, up 12.7% from Q2 last year, reflecting large enterprise orders in life sciences. The trailing 12-month book-to-bill ratio was 1.05 to 1, and total order backlog was approximately $2 billion, up sequentially from Q1.

Negative Updates

Revenue and Operating Earnings Declined
Q2 revenue was $666 million, down 8.6% from last year. Adjusted earnings from operations were $57.4 million, down 27.4%, while adjusted operating margin declined to 8.6% from 10.9%, primarily due to mix and absorption.

Company Guidance

For fiscal 27, ATS said it does not expect to achieve its previous goals for modest revenue growth and for margin expansion in the year; third quarter revenues are expected to be in the range of $640 million to $680 million. The fixed cost transformation program is expected to deliver $65 million to $75 million of annualized savings, or roughly 250 basis points of margin expansion, from a base of 10%, representing approximately half of the path to the adjusted earnings from operations margin target of 15%, with implementation continuing over the next 15 months. Announced actions are expected to reduce square footage by approximately 10% and result in a workforce reduction, including subcontractors, of 300 to 400 globally; payback on restructuring is expected to be less than 1 year overall. Fiscal 27 CapEx and intangible investment is expected to be between $60 million and $80 million, leverage is expected to operate moderately above the target leverage range of 2 to 3 times during the remainder of fiscal 27, and working capital is expected to stay within the long term target of 15% or less through the back half of the year.

ATS Corporation Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

ATS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:SISTSE:SIS69NeutralCAD 2.24B24.4813.41%1.88%8.16%47.17%
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
TSE:PYRTSE:PYR55NeutralCAD 45.27M-3.87112.32%―11.62%16.81%
TSE:BLDPTSE:BLDP51NeutralCAD 775.91M-5.70-13.16%―45.07%73.98%
TSE:VLNTSE:VLN45NeutralCAD 377.53M-10.58-14.80%3.20%-9.05%73.48%
TSE:DYATSE:DYA43NeutralCAD 50.83M-4.92718.52%―-57.68%24.90%

* Industrials Sector Average

Performance Comparison

0%100%200%ATSTSE:BLDPTSE:DYATSE:PYRTSE:SISTSE:VLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ATS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ATSAts Corporation16.97-10.44-38.09%
TSE:BLDPBallard Power2.16-2.81-56.54%
TSE:DYAdynaCERT Inc0.09-0.03-25.00%
TSE:PYRPyroGenesis Canada0.19-0.02-9.52%
TSE:SISSavaria Corp.29.727.7435.21%
TSE:VLNVelan Inc. SV17.751.046.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.